Disclosures: Min Kyung Chu: nothing to disclose. Dawn C. Buse has received honoraria from Allergan Pharmaceuticals, ENDO Pharmaceuticals, Iroko Pharmacetuicals, Merck, Inc., and MAP Pharmaceuticals. Richard B. Lipton has received grants or honoraria from Advanced Bionics, Allergan Pharmaceuticals, Endo Pharmaceuticals, GlaxoSmithKline, Minster, Merck, Inc., Neuralieve, Novartis, OrthoMcNeil, Pfizer, ProEthics/KOWA, the National Headache Foundation, and the National Institutes of Health. He has received honoraria from Allergan Pharmaceuticals, AstraZeneca, Endo Pharmaceuticals, GlaxoSmithKline, Merck, Inc., Novartis, OrthoMcNeil, and Pfizer. Marcelo E. Bigal is a full-time employee of Merck, Inc. He owns stocks and stock options of Merck. Daniel Serrano has provided statistical and consulting support to Allergan, Merck, GlaxoSmithKline, ENDO Pharmaceuticals, and Ortho-McNeil Neurologics.
Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study
Article first published online: 15 NOV 2011
© 2011 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 52, Issue 2, pages 213–223, February 2012
How to Cite
Chu, M. K., Buse, D. C., Bigal, M. E., Serrano, D. and Lipton, R. B. (2012), Factors Associated With Triptan Use in Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study. Headache: The Journal of Head and Face Pain, 52: 213–223. doi: 10.1111/j.1526-4610.2011.02032.x
Sponsorship: The American Migraine Prevalence and Prevention Study is funded through a research grant to the National Headache Foundation from Ortho-McNeil Neurologics, Inc., Titusville, NJ, USA. Additional analyses and article preparation were supported through a grant from Merck & Co., Inc., Whitehouse Station, NJ, USA, to the National Headache Foundation.
- Issue published online: 6 FEB 2012
- Article first published online: 15 NOV 2011
- Accepted for publication July 27, 2011.
- acute treatment;
- headache-related disability;
- preventive treatment
Background.— Though triptans are considered the standard of acute therapy for migraine attacks with headache-related disability, they are used by the minority of potentially eligible persons. Understanding the socio-demographic and headache features that predict triptan use may help to clarify barriers to optimal treatment.
Objective.— To assess the sociodemographic and headache features associated with triptan use in a US population sample of persons with episodic migraine.
Methods.— The American Migraine Prevalence and Prevention Study (AMPP) is a longitudinal study conducted in a representative sample of US headache sufferers. Episodic migraineurs (n = 11,388) who provided treatment data in 2005 were included in the current analyses. We assessed factors associated with triptan use through univariate and multivariate analyses. Multivariate analyses were adjusted for sociodemographic factors, headache-related disability, cutaneous allodynia, depression, and preventive headache medication use.
Results.— Among persons with episodic migraine, 18.31% reported current use of triptans for acute headache treatment. In univariate analyses, triptan use was most common in midlife (ages 30-59), among females, and was more common in Caucasians than in African Americans. Triptan use increased with headache frequency, headache-related disability and allodynia, but decreased among persons with depression. In multivariate analyses, female gender, Caucasian race, age 40-49, higher levels of education (college or higher), annual household income of ≥$40,000, having health insurance, the presence of cutaneous allodynia, greater headache-related disability, and preventive medication use for migraine were significantly associated with triptan use.
Conclusions.— Less than 1 in 5 persons with migraine in the United States who were respondents to this survey used triptans for acute headache treatment over the course of a year. Several markers of severe headache, including disability and allodynia, were associated with increased triptan use. Groups less likely to get triptans included males, African Americans, older adults, and the uninsured. Predictors of use provide insight into groups with unmet treatment needs.